CytomX Therapeutics reported robust progress in its third quarter 2025 results, with encouraging interim Phase I data for its colorectal cancer drug candidate, CX-2051, demonstrating significant clinical activity and a well-tolerated safety profile.

• CX-2051, targeting EpCAM in colorectal cancer, showed meaningful tumor reductions and a promising median progression-free survival of 5.8 months.
• The drug was generally well tolerated, with no significant safety issues, implying effective use of CytomX's proprietary masking technology.
• The company aims to expand the Phase I study to about 100 patients and initiate a Phase Ib study with bevacizumab in Q1 2026, enhancing treatment potential.
• A strategic addition to the team, Rachael Lester as Chief Business Officer, is expected to bolster corporate development efforts.
• CytomX remains committed to addressing unmet needs in oncology, with ambitions to establish CX-2051 as a new standard of care in late-stage colorectal cancer.